PolyPid Ltd (NASDAQ:PYPD) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Douglas Buchanan - JMP Securities Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. Brian Ritchie Earlier today, PolyPid released financial results for the 3 and 6 months ended June 30, 2023. A copy of the press release is available in the Investors section on the company's website, www.poly ...

Executive Vice President heading R&D, and Clinical & Regulatory Affairs Balance Sheet • An early stop to the trial can occur if the efficacy of DPLEX100 is better than expected • Opportunity to define the targeted patient enrollment range for the SHIELD I study 5 Total US addressable market (TAM) for D-PLEX100 is over 12.2M procedures Number of surgeries in DPLEX target indications (M) 4.42 12.15 2.44 0.47 4.82 Abdominal Gyn & Uro Sternum Orthopedic Total | --- | --- | |-------|----------------------------- ...

PolyPid Ltd. (NASDAQ:PYPD) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Roy Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid First Quarter 2023 Conference Call. At this time participants are in a listen-only mode. As a remi ...

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 5, 2023 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company”) for use at the Company’s annual and extraordinary general meeting of shareholders (the “Meeting”) to be held on May 5, 2023, at 2:00 p.m. Israel time, or at any adjournment or postponement thereof. Upon the receipt of a properly executed proxy ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...

PolyPid Ltd (NASDAQ:PYPD) Q4 2022 Earnings Conference Call February 8, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon Folkes - Cantor Fitzgerald Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions]. As a reminder, this call is recorded. And I would now like to introduc ...

PolyPid Ltd. (NASDAQ:PYPD) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, U.S. Operations Conference Call Participants Brandon Folkes - Cantor Fitzgerald Elliot Wilbur - Raymond James Roy Buchanan - JMP Securities Bob Yedid Thank you all for participating in PolyPid's Third Quarter 2022 Earnings Conference Call. Joining me on the cal ...

PolyPid Ltd. (NASDAQ:PYPD) Q2 2022 Results Conference Call August 10, 2022 8:30 AM ET Company Participants Bob Yedid - IR, LifeSci Advisors Dikla Czaczkes Akselbrad - CEO Ori Warshavsky - COO, U.S. Operations Conference Call Participants Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Michael Parolari - Raymond James Roy Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2022 Conference Call. [Operator Instructions] A reminder, this call is recorded ...

| --- | --- | --- | |------------------------|-------|-------| | | | | | | | | | P&LYPID | | | | | | 电 | | CORPORATE PRESENTATION | | | | | | | OPTIMIZED THERAPEUTICS JUNE 2022 Disclaimer This presentation of PolyPid Ltd. (the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such wor ...

PolyPid Ltd. (NASDAQ:PYPD) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad - Executive Vice President and Chief Financial Officer Ori Warshavsky - Chief Operating Officer, US Operations Conference Call Participants Balaji Prasad - Barclays Michael Parolari - Raymond James Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Roy Buchanan - JMP Securi ...